Roche's Product Pipeline Is Firing on All Cylinders - UBS Just Says the Market Already Knows - ad-hoc-news.de
Article excerpt
Roche closed recruitment this week for the Phase III ENVISION trial of Elevidys in older ambulatory and non-ambulatory Duchenne patients, a study that enrolled 90 participants across 14 countries. The company and partner Sarepta Therapeutics are now analyzing data from the first part of the trial. It is one of several pipeline and regulatory developments that have landed in quick succession - and that together frame the central question facing investors: how much of this progress is already reflected in the share price? UBS delivered its verdict on Monday, cutting its rating on the Swiss drugmaker from "Buy" to "Neutral" while simultaneously lifting its price target to CHF 420 from CHF 376. According to media reports, the bank pointed to valuation following the stock's recent rally as the reason for the more cautious stance. Its medium-term thesis on Giredestrant, notably, remained intact - a combination that captures the tension neatly: a positive view of a drug candidate can coexist with a reserved view of the equity if the market has already priced in the expected progress. That tension has real weight, because Roche shares have climbed 20% since the start of the year. The advance makes the valuation debate especially pertinent for anyone considering a fresh position, even if it does not by itself settle the stock's appeal. The pipeline news flow has been broad. On Monday...
Keep reading with a free account
The rest of this article, and every signal for Roche, is in your free account.
Extracted from this sentence
Chai Discovery announced a collaboration on Tuesday under which Roche will deploy Chai's AI models and platform across multiple drug discovery programs; financial terms and the specific programs were not disclosed.
